In the BioHarmony Drug Report Database

"Preview" Icon

Octreotide

Mycapssa, Sandostatin, Sandostatin Lar, SomaKit TOC (octreotide) is a protein pharmaceutical. Octreotide was first approved as Mycapssa on 1988-10-21. It is used to treat acromegaly, adenoma, diarrhea, pancreatic neoplasms, and pituitary neoplasms in the USA. It has been approved in Europe to treat neuroendocrine tumors and radionuclide imaging. The pharmaceutical is active against somatostatin receptor type 2. In addition, it is known to target somatostatin receptor type 3 and somatostatin receptor type 5. Sandostatin’s patents are valid until 2036-02-03 (FDA).

 

Trade Name

 

SomaKit TOC
 

Common Name

 

octreotide
 

ChEMBL ID

 

CHEMBL1680
 

Indication

 

acromegaly, adenoma, diarrhea, neuroendocrine tumors, pancreatic neoplasms, pituitary neoplasms, radionuclide imaging
 

Drug Class

 

Peptides: inhibition of growth hormone release

Image (chem structure or protein)

Octreotide structure rendering